We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microarray Platform Demonstrates High Performance and Cost Effectiveness

By Labmedica staff writers
Posted on 01 Apr 2008
An objective comparison of tiling microarray array platforms using engineered DNA targets demonstrated their high performance and cost effectiveness.

The study organized by members of the Encyclopedia of DNA Elements consortium (ENCODE; Bethesda, MD, USA) at the University of North Carolina at Chapel Hill (Chapel Hill, NC, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and Stanford University (Stanford, CA, USA) evaluated DNA microarrays from Agilent (Santa Clara, CA, USA), Affymetrix (Santa Clara, CA, USA), and Nimblegen (Madison, WI, USA), which were used in seven independent laboratories.

The composition of the spike-in DNA in this study was engineered to mimic chromatin immunoprecipitation (ChIP) or copy-number amplification experiments across a wide dynamic range. More...
To ensure a fair evaluation, the composition was not disclosed to participants. This made it possible to quantitatively evaluate each platform's sensitivity and specificity of detecting and quantifying a predefined standard without bias.

Platforms were compared using their highest possible tiling density. In evaluating results from comparable algorithms, Agilent consistently achieved the highest or equivalent scores, but did so with fewer probes, half as many replicates, and less sample DNA than either of the other platforms.

The study found that longer oligonucleotide (60-nt) microarrays, such as Agilent's, were more sensitive at detecting very low enrichment or copy number. Additionally, Agilent demonstrated the highest levels of sensitivity and specificity per probe, in some cases by orders of magnitude, over a range of simulated tiling densities.

"Agilent proved to be the most cost-effective of the long-oligo platforms over a wide range of tiling densities relevant to not only ChIP-on-chip assays but also to aCGH [array comparative genomic hybridization],” said Yvonne Linney, Ph.D., VP and general manager of Agilent's Genomics business. "The cost advantage is the result of our superior probe performance, which is due to the high quality of our SurePrint in situ oligonucleotide synthesis combined with our robust probe design algorithms. The bottom line is that the increased performance of Agilent's probes makes it possible to get more data with fewer features.”

The study was published in the journal Genome Research in March 2008.


Related Links:
Encyclopedia of DNA Elements consortium
University of North Carolina
Dana-Farber Cancer Institute

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.